AstraZeneca begins trials for a modified booster vaccine against a beta version of COVID-19. On Sunday, AstraZeneca and the University of Oxford began new trials to test an improved vaccine against the beta form, which was first discovered in South Africa.
Around 2,250 people from the United Kingdom, South Africa, Brazil and Poland will participate in the ‘booster’ vaccine trial. Individuals in the trial will include those who have received the original Oxford-AstraZeneca vaccination or two doses of the Pfizer mRNA vaccine, as well as those who have not received the vaccine at all.
Andrew Pollard, principal investigator and director of the Oxford Vaccine Group, said: “Testing booster doses of existing vaccines and a new version, vaccines, are critical to ensuring that we are prepared to stay ahead of the pandemic coronavirus, the need for their use.” Should be.” at Oxford University.
According to country experts, even after a successful UK vaccine rollout program, there remains uncertainty about how long the protection of the vaccine will last in a person’s body.
According to Maheshi Ramasamy, principal investigator of the Oxford Vaccine Group, “this study will provide important evidence on whether further doses, including ‘tweaks’, may be needed against new virus variants in the future”.
The first results of these trials are expected to be released later this year.
Existing vaccines are considered to be less effective than the beta version, however, the delta version being developed in India is the cause of most concern right now.
Despite the fact that primary vaccines are known to be highly efficient in preventing serious disease, the infectious characteristics of the delta variant have resulted in an increase in cases in some countries, including the United Kingdom. Britain saw an increase of 35,204 cases in the past week, bringing the total number of cases to 111,157.
See below health equipment-
Calculate your body mass index (BMI)
.